Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study supports genetic testing in older women with breast cancer

Publish date:: November 10, 2020

Key clinical point: The prevalence of pathogenic variants in breast cancer–predisposing genes is “not negligible” in women older than 65 years.

Major finding: Variants in breast cancer-disposing genes (such as BRCA1/2, CHEK2, and PALB2) were found in 3.18% of women with breast cancer and 1.48% of women without breast cancer.

Study details: A case-control study of 26,707 women older than 65 years – 13,762 with and 12,945 without breast cancer.

Disclosures: The study was funded by the National Institutes of Health. The lead investigator didn’t have any disclosures.

Citation:

Boddicker NJ et al. ASHG 2020, Abstract 2412.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,